Download PDF
CC BY 4.0 · Glob Med Genet 2022; 09(02): 090-096
DOI: 10.1055/s-0042-1743567
Review Article

Genetic Variants and Drug Efficacy in Tuberculosis: A Step toward Personalized Therapy

Almas Khan
1   Department of Personalized and Molecular Medicine, Era University, Lucknow, Uttar Pradesh, India
,
Mohammad Abbas
1   Department of Personalized and Molecular Medicine, Era University, Lucknow, Uttar Pradesh, India
,
Sushma Verma
1   Department of Personalized and Molecular Medicine, Era University, Lucknow, Uttar Pradesh, India
,
Shrikant Verma
1   Department of Personalized and Molecular Medicine, Era University, Lucknow, Uttar Pradesh, India
,
Aliya Abbas Rizvi
1   Department of Personalized and Molecular Medicine, Era University, Lucknow, Uttar Pradesh, India
,
Fareya Haider
3   Department of Microbiology, Era's Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India
,
Syed Tasleem Raza
2   Department of Biochemistry, Era's Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India
,
Farzana Mahdi
1   Department of Personalized and Molecular Medicine, Era University, Lucknow, Uttar Pradesh, India
› Author Affiliations Funding None.
› Further Information
   Permissions and Reprints

Abstract

Tuberculosis (TB) continues to be a major infectious disease affecting individuals worldwide. Current TB treatment strategy recommends the standard short-course chemotherapy regimen containing first-line drug, i.e., isoniazid, rifampicin, pyrazinamide, and ethambutol to treat patients suffering from drug-susceptible TB. Although Mycobacterium tuberculosis, the causing agent, is susceptible to drugs, some patients do not respond to the treatment or treatment may result in serious adverse reactions. Many studies revealed that anti-TB drug-related toxicity is associated with genetic variations, and these variations may also influence attaining maximum drug concentration. Thus, inter-individual diversities play a characteristic role by influencing the genes involved in drug metabolism pathways. The development of pharmacogenomics could bring a revolution in the field of treatment, and the understanding of germline variants may give rise to optimized targeted treatments and refine the response to standard therapy. In this review, we briefly introduced the field of pharmacogenomics with the evolution in genetics and discussed the pharmacogenetic impact of genetic variations on genes involved in the activities, such as anti-TB drug transportation, metabolism, and gene regulation.

Keywords

mycobacterium tuberculosis - germline variants - anti-TB drug-related toxicity - pharmacogenomics - personalized medicine


Publication History

Received: 22 December 2021

Accepted: 21 January 2022

Article published online:
25 February 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: from the first historical records to the isolation of Koch's bacillus. J Prev Med Hyg 2017; 58 (01) E9-E12
    PubMedGoogle Scholar
  • 2 World Health Organisation report, 2020. Accessed September 27, 2021 at: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf
    Google Scholar
  • 3 Ramamoorthy A, Pacanowski MA, Bull J, Zhang L. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther 2015; 97 (03) 263-273
    CrossrefPubMedGoogle Scholar
  • 4 Relling MV, Giacomini KM. Pharmacogenetics. In: Brunton LL, Lazo GS, Parker KL. eds. Goodman & Gilman's. The Pharmacological Basis of Therapeutics, XI edizione. New York: McGraw-Hill Medical Publishing Division; 2006. , chapter 4: 93-115
    Google Scholar
  • 5 Bachtiar M, Ooi BNS, Wang J. et al. Towards precision medicine: interrogating the human genome to identify drug pathways associated with potentially functional, population-differentiated polymorphisms. Pharmacogenomics J 2019; 19 (06) 516-527
    CrossrefPubMedGoogle Scholar
  • 6 Barbarino JM, Whirl-Carrillo M, Altman RB, Klein TE. PharmGKB: a worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med 2018; 10 (04) e1417
    CrossrefPubMedGoogle Scholar
  • 7 O'Donnell PH, Dolan ME. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009; 15 (15) 4806-4814
    CrossrefPubMedGoogle Scholar
  • 8 Getahun H, Matteelli A, Abubakar I. et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J 2015; 46 (06) 1563-1576
    CrossrefPubMedGoogle Scholar
  • 9 Dompreh A, Tang X, Zhou J. et al. Effect of genetic variation of NAT2 on isoniazid and SLCO1B1 and CES2 on rifampin pharmacokinetics in Ghanaian children with tuberculosis. Antimicrob Agents Chemother 2018; 62 (03) e02099-17
    PubMedGoogle Scholar
  • 10 Metushi IG, Cai P, Zhu X, Nakagawa T, Uetrecht JP. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 2011; 89 (06) 911-914
    CrossrefPubMedGoogle Scholar
  • 11 Carlson HB, Anthony EM, Russell Jr WF, Middlebrook G. Prophylaxis of isoniazid neuropathy with pyridoxine. N Engl J Med 1956; 255 (03) 119-122
    CrossrefPubMedGoogle Scholar
  • 12 Lander ES, Linton LM, Birren B. et al; International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409 (6822): 860-921
    CrossrefPubMedGoogle Scholar
  • 13 Venter JC, Adams MD, Myers EW. et al. The sequence of the human genome. Science 2001; 291 (5507): 1304-1351
    CrossrefPubMedGoogle Scholar
  • 14 Wilke RA, Lin DW, Roden DM. et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007; 6 (11) 904-916
    CrossrefPubMedGoogle Scholar
  • 15 Court MH. A pharmacogenomics primer. J Clin Pharmacol 2007; 47 (09) 1087-1103
    CrossrefPubMedGoogle Scholar
  • 16 Sloan DJ, McCallum AD, Schipani A. et al. Genetic determinants of the pharmacokinetic variability of rifampin in Malawian adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2017; 61 (07) e00210-e00217
    CrossrefPubMedGoogle Scholar
  • 17 Thomas L, Miraj SS, Surulivelrajan M, Varma M, Sanju CSV, Rao M. Influence of single nucleotide polymorphisms on rifampin pharmacokinetics in tuberculosis patients. Antibiotics (Basel) 2020; 9 (06) 307
    CrossrefPubMedGoogle Scholar
  • 18 Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979; 4 (06) 401-422
    CrossrefPubMedGoogle Scholar
  • 19 Murray JF, Schraufnagel DE, Hopewell PC. Treatment of tuberculosis. A historical perspective. Ann Am Thorac Soc 2015; 12 (12) 1749-1759
    CrossrefPubMedGoogle Scholar
  • 20 Maggi N, Pasqualucci CR, Ballotta R, Sensi P. Rifampicin: a new orally active rifamycin. Chemotherapy 1966; 11 (05) 285-292
    CrossrefPubMedGoogle Scholar
  • 21 Campbell EA, Korzheva N, Mustaev A. et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001; 104 (06) 901-912
    CrossrefPubMedGoogle Scholar
  • 22 Zaw MT, Emran NA, Lin Z. Mutations inside rifampicin-resistance determining region of rpoB gene associated with rifampicin-resistance in Mycobacterium tuberculosis. J Infect Public Health 2018; 11 (05) 605-610
    CrossrefPubMedGoogle Scholar
  • 23 Gumbo T, Louie A, Deziel MR. et al. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51 (11) 3781-3788
    CrossrefPubMedGoogle Scholar
  • 24 Stott KE, Pertinez H, Sturkenboom MGG. et al. Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis. J Antimicrob Chemother 2018; 73 (09) 2305-2313
    CrossrefPubMedGoogle Scholar
  • 25 Seijger C, Hoefsloot W, Bergsma-de Guchteneire I. et al. High-dose rifampicin in tuberculosis: experiences from a Dutch tuberculosis centre. PLoS One 2019; 14 (03) e0213718
    CrossrefPubMedGoogle Scholar
  • 26 Svensson EM, Svensson RJ, Te Brake LHM. et al. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis. Clin Infect Dis 2018; 67 (01) 34-41
    CrossrefPubMedGoogle Scholar
  • 27 Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur J Clin Invest 2003; 33 (Suppl. 02) 1-5
    CrossrefPubMedGoogle Scholar
  • 28 Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 2003; 304 (01) 223-228
    CrossrefPubMedGoogle Scholar
  • 29 Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci 2006; 95 (06) 1177-1195
    CrossrefPubMedGoogle Scholar
  • 30 Nakajima A, Fukami T, Kobayashi Y, Watanabe A, Nakajima M, Yokoi T. Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifampicin, rifabutin, and rifapentine. Biochem Pharmacol 2011; 82 (11) 1747-1756
    CrossrefPubMedGoogle Scholar
  • 31 Boivin AA, Cardinal H, Barama A, Pichette V, Hébert MJ, Roger M. Organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3: genetic variability and haplotype analysis in white Canadians. Drug Metab Pharmacokinet 2010; 25 (05) 508-515
    CrossrefPubMedGoogle Scholar
  • 32 Giacomini KM, Huang SM, Tweedie DJ. et al; International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9 (03) 215-236
    CrossrefPubMedGoogle Scholar
  • 33 Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007; 8 (07) 787-802
    CrossrefPubMedGoogle Scholar
  • 34 Vavricka SR, Van Montfoort J, Ha HR, Meier PJ, Fattinger K. Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology 2002; 36 (01) 164-172
    CrossrefPubMedGoogle Scholar
  • 35 Hillgren KM, Keppler D, Zur AA. et al; International Transporter Consortium. Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther 2013; 94 (01) 52-63
    CrossrefPubMedGoogle Scholar
  • 36 Guo YX, Xu XF, Zhang QZ. et al. The inhibition of hepatic bile acids transporters Ntcp and Bsep is involved in the pathogenesis of isoniazid/rifampicin-induced hepatotoxicity. Toxicol Mech Methods 2015; 25 (05) 382-387
    CrossrefPubMedGoogle Scholar
  • 37 Te Brake LH, Russel FG, van den Heuvel JJ. et al. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters. Tuberculosis (Edinb) 2016; 96: 150-157
    CrossrefPubMedGoogle Scholar
  • 38 Internet source. Accessed on September 1, 2021 at: www.hapman.com
    Google Scholar
  • 39 Oshiro C, Mangravite L, Klein T, Altman R. PharmGKB very important pharmacogene: SLCO1B1. Pharmacogenet Genomics 2010; 20 (03) 211-216
    CrossrefPubMedGoogle Scholar
  • 40 Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011; 63 (01) 157-181
    CrossrefPubMedGoogle Scholar
  • 41 Allegra S, Fatiguso G, Calcagno A. et al. Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. Pharmacogenomics 2017; 18 (09) 865-880
    CrossrefPubMedGoogle Scholar
  • 42 Weiner M, Peloquin C, Burman W. et al. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations. Antimicrob Agents Chemother 2010; 54 (10) 4192-4200
    CrossrefPubMedGoogle Scholar
  • 43 Lee HH, Ho RH. Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1). Br J Clin Pharmacol 2017; 83 (06) 1176-1184
    CrossrefPubMedGoogle Scholar
  • 44 Dompreh A, Tang X, Zhou J. et al. Effect of genetic variation of NAT2 on isoniazid and SLCO1B1 and CES2 on rifampin pharmacokinetics in Ghanaian children with tuberculosis. Antimicrob Agents Chemother 2018; 62 (03) e02099-e17
    CrossrefPubMedGoogle Scholar
  • 45 Chigutsa E, Visser ME, Swart EC. et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 2011; 55 (09) 4122-4127
    CrossrefPubMedGoogle Scholar
  • 46 Gengiah TN, Botha JH, Soowamber D, Naidoo K, Abdool Karim SS. Low rifampicin concentrations in tuberculosis patients with HIV infection. J Infect Dev Ctries 2014; 8 (08) 987-993
    CrossrefPubMedGoogle Scholar
  • 47 Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci USA 1996; 93 (09) 4001-4005
    CrossrefPubMedGoogle Scholar
  • 48 Jones PM, George AM. The ABC transporter structure and mechanism: perspectives on recent research. Cell Mol Life Sci 2004; 61 (06) 682-699
    CrossrefPubMedGoogle Scholar
  • 49 Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995; 29: 607-649
    CrossrefPubMedGoogle Scholar
  • 50 Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet 2015; 54 (07) 709-735
    CrossrefPubMedGoogle Scholar
  • 51 Caraba A, Crişan V, Romoşan I, Mozoş I, Murariu M. Vitamin D status, disease activity, and endothelial dysfunction in early rheumatoid arthritis patients. Dis Markers 2017; 2017: 5241012
    CrossrefPubMedGoogle Scholar
  • 52 Hodges LM, Markova SM, Chinn LW. et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics 2011; 21 (03) 152-161
    CrossrefPubMedGoogle Scholar
  • 53 Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. Biochim Biophys Acta 2009; 1794 (05) 860-871
    CrossrefPubMedGoogle Scholar
  • 54 Jinno H, Tanaka-Kagawa T, Hanioka N. et al. Identification of novel alternative splice variants of human constitutive androstane receptor and characterization of their expression in the liver. Mol Pharmacol 2004; 65 (03) 496-502
    CrossrefPubMedGoogle Scholar
  • 55 Jamis-Dow CA, Katki AG, Collins JM, Klecker RW. Rifampin and rifabutin and their metabolism by human liver esterases. Xenobiotica 1997; 27 (10) 1015-1024
    CrossrefPubMedGoogle Scholar
  • 56 Ross MK, Crow JA. Human carboxylesterases and their role in xenobiotic and endobiotic metabolism. J Biochem Mol Toxicol 2007; 21 (04) 187-196
    CrossrefPubMedGoogle Scholar
  • 57 Wang D, Zou L, Jin Q, Hou J, Ge G, Yang L. Human carboxylesterases: a comprehensive review. Acta Pharm Sin B 2018; 8 (05) 699-712
    CrossrefPubMedGoogle Scholar
  • 58 Merali Z, Ross S, Paré G. The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect. Drug Metabol Drug Interact 2014; 29 (03) 143-151
    CrossrefPubMedGoogle Scholar
  • 59 Song SH, Chang HE, Jun SH. et al. Relationship between CES2 genetic variations and rifampicin metabolism. J Antimicrob Chemother 2013; 68 (06) 1281-1284
    CrossrefPubMedGoogle Scholar
  • 60 Mitchison DA. Plasma concentrations of isoniazid in the treatment of tuberculosis. In: Davies DS, Prichard BN. eds. Biological Effects of Drugs in Relation to their Plasma Concentrations. London: MacMillan; 1973: 171-182
    Google Scholar
  • 61 Ellard GA, Gammon PT. Pharmacokinetics of isoniazid metabolism in man. J Pharmacokinet Biopharm 1976; 4 (02) 83-113
    CrossrefPubMedGoogle Scholar
  • 62 Bhandari R, Kaur IP. Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm 2013; 441 (1-2): 202-212
    CrossrefPubMedGoogle Scholar
  • 63 Hutchings AD, Monie RD, Spragg BP, Routledge PA. Saliva and plasma concentrations of isoniazid and acetylisoniazid in man. Br J Clin Pharmacol 1988; 25 (05) 585-589
    CrossrefPubMedGoogle Scholar
  • 64 Jutte PC, Rutgers SR, Van Altena R, Uges DR, Van Horn JR. Penetration of isoniazid, rifampicin and pyrazinamide in tuberculous pleural effusion and psoas abscess. Int J Tuberc Lung Dis 2004; 8 (11) 1368-1372
    PubMedGoogle Scholar
  • 65 Conte Jr JE, Golden JA, McQuitty M. et al. Effects of gender, AIDS, and acetylator status on intrapulmonary concentrations of isoniazid. [published correction appears in Antimicrob Agents Chemother. 2002 Sep;46(9):3112.] Antimicrob Agents Chemother 2002; 46 (08) 2358-2364
    CrossrefPubMedGoogle Scholar
  • 66 Singh N, Golani A, Patel Z, Maitra A. Transfer of isoniazid from circulation to breast milk in lactating women on chronic therapy for tuberculosis. Br J Clin Pharmacol 2008; 65 (03) 418-422
    CrossrefPubMedGoogle Scholar
  • 67 Wang P, Pradhan K, Zhong XB, Ma X. Isoniazid metabolism and hepatotoxicity. Acta Pharm Sin B 2016; 6 (05) 384-392
    CrossrefPubMedGoogle Scholar
  • 68 Khan SR, Morgan AG, Michail K. et al. Metabolism of isoniazid by neutrophil myeloperoxidase leads to isoniazid-NAD(+) adduct formation: a comparison of the reactivity of isoniazid with its known human metabolites. Biochem Pharmacol 2016; 106: 46-55
    CrossrefPubMedGoogle Scholar
  • 69 Rozwarski DA, Grant GA, Barton DH, Jacobs Jr WR, Sacchettini JC. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 1998; 279 (5347): 98-102
    CrossrefPubMedGoogle Scholar
  • 70 Khan N, Pande V, Das A. NAT2 sequence polymorphisms and acetylation profiles in Indians. Pharmacogenomics 2013; 14 (03) 289-303
    CrossrefPubMedGoogle Scholar
  • 71 Preziosi P. Isoniazid: metabolic aspects and toxicological correlates. Curr Drug Metab 2007; 8 (08) 839-851
    CrossrefPubMedGoogle Scholar
  • 72 Cheng J, Krausz KW, Li F, Ma X, Gonzalez FJ. CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid. Toxicol Appl Pharmacol 2013; 266 (02) 245-253
    CrossrefPubMedGoogle Scholar
  • 73 Sim E, Payton M, Noble M, Minchin R. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes. Hum Mol Genet 2000; 9 (16) 2435-2441
    CrossrefPubMedGoogle Scholar
  • 74 Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol 1990; 9 (03) 193-203
    CrossrefPubMedGoogle Scholar
  • 75 Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltransferases from human liver. J Biol Chem 1990; 265 (08) 4630-4634
    CrossrefPubMedGoogle Scholar
  • 76 Windmill KF, Gaedigk A, Hall PM, Samaratunga H, Grant DM, McManus ME. Localization of N-acetyltransferases NAT1 and NAT2 in human tissues. Toxicol Sci 2000; 54 (01) 19-29
    CrossrefPubMedGoogle Scholar
  • 77 Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS One 2011; 6 (04) e18507
    CrossrefPubMedGoogle Scholar
  • 78 Boukouvala S, Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin Pharmacol Toxicol 2005; 96 (05) 343-351
    CrossrefPubMedGoogle Scholar
  • 79 Hein DW. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene 2006; 25 (11) 1649-1658
    CrossrefPubMedGoogle Scholar
  • 80 Richardson M, Kirkham J, Dwan K, Sloan D, Davies G, Jorgensen A. Influence of genetic variants on toxicity to anti-tubercular agents: a systematic review and meta-analysis (protocol). Syst Rev 2017; 6 (01) 142
    CrossrefPubMedGoogle Scholar
  • 81 Donald PR, Parkin DP, Seifart HI. et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 2007; 63 (07) 633-639
    CrossrefPubMedGoogle Scholar